We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
NOVALTO (Nova Pharmaceuticals Australasia Pty Ltd)
Product name
NOVALTO
Date registered
Evaluation commenced
Decision date
Approval time
133 (255 working days)
Active ingredients
rivaroxaban
Registration type
New generic medicine
Indication
TRADE NAME is indicated for:
- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of recurrent DVT and PE.